Back to Search Start Over

Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys.

Authors :
Wang, H.-B.
Kondo, A.
Yoshida, A.
Yoshizaki, S.
Abe, S.
Bao, L.-L.
Mizuki, N.
Ichino, M.
Klinman, D.
Okuda, K.
Shimada, M.
Source :
Gene Therapy; Jan2010, Vol. 17 Issue 1, p4-13, 10p, 8 Graphs
Publication Year :
2010

Abstract

This study explores the effect of priming rhesus monkeys with an Ad5/35 vector expressing simian immunodeficiency virus (SIV) gag and gp120, and then boosting the animals with an modified vaccinia virus Ankara (MVA) vector encoding the same antigens after a 2-month interval. The animals were intravenously challenged with 100 TCID50 of highly pathogenic SIVmac239 virus 2 months after the booster vaccination. The priming vaccination induced robust SIV-specific cell-mediated and humoral immune responses, and boosting further enhanced the cellular immunity. Vaccination reduced peak and long-term viral loads by 1–2 logs for a period of >6 months, as reflected by a reduction in both the SIV RNA and DNA levels. Of considerable interest, the immunized monkeys did not suffer from loss of CD4 T cells, particularly central memory CD4 T cells. These results demonstrate that prophylactic vaccination with Ad5/35 followed by MVA reduces viral replication and prevents CD4 T-cell loss, and that these effects may decrease the likelihood of disease progression. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09697128
Volume :
17
Issue :
1
Database :
Complementary Index
Journal :
Gene Therapy
Publication Type :
Academic Journal
Accession number :
47342920
Full Text :
https://doi.org/10.1038/gt.2009.122